Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Omnicell Inc (OMCL)

Omnicell Inc (OMCL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,116,224
  • Shares Outstanding, K 46,317
  • Annual Sales, $ 1,147 M
  • Annual Income, $ -20,370 K
  • EBIT $ -35 M
  • EBITDA $ 65 M
  • 60-Month Beta 0.81
  • Price/Sales 1.78
  • Price/Cash Flow 14.03
  • Price/Book 1.66

Options Overview Details

View History
  • Implied Volatility 56.87% ( +18.97%)
  • Historical Volatility 94.98%
  • IV Percentile 47%
  • IV Rank 36.35%
  • IV High 94.83% on 04/16/24
  • IV Low 35.19% on 06/20/24
  • Put/Call Vol Ratio 0.67
  • Today's Volume 55
  • Volume Avg (30-Day) 218
  • Put/Call OI Ratio 1.00
  • Today's Open Interest 4,211
  • Open Int (30-Day) 4,658

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.34
  • Number of Estimates 3
  • High Estimate 0.38
  • Low Estimate 0.28
  • Prior Year 0.12
  • Growth Rate Est. (year over year) +183.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
39.05 +17.00%
on 10/24/24
55.74 -18.04%
on 10/30/24
+4.59 (+11.17%)
since 10/22/24
3-Month
39.05 +17.00%
on 10/24/24
55.74 -18.04%
on 10/30/24
+3.17 (+7.46%)
since 08/22/24
52-Week
25.12 +81.89%
on 07/09/24
55.74 -18.04%
on 10/30/24
+12.07 (+35.90%)
since 11/22/23

Most Recent Stories

More News
CLOV Q3 Estimates Unchanged Before Earnings: How to Play the Stock?

Clover Health Investments, Corp. CLOV is scheduled to report third-quarter 2024 results on Nov. 6, after the closing bell.In the last reported quarter, the company delivered earnings per share of a penny...

OMCL : 45.69 (+3.58%)
PHR : 19.87 (+4.58%)
AXNX : 70.98 (+0.75%)
CLOV : 3.37 (+0.30%)
Omnicell: Q3 Earnings Snapshot

Omnicell: Q3 Earnings Snapshot

OMCL : 45.69 (+3.58%)
Best Momentum Stocks to Buy for October 4th

Here are two stocks with buy rank and strong momentum characteristics for investors to consider today, October 4:Omnicell, Inc. OMCL: This pharmaceutical technology company has a Zacks Rank #1 and witnessed...

OMCL : 45.69 (+3.58%)
SFBS : 96.64 (+3.64%)
Omnicell: Q2 Earnings Snapshot

Omnicell: Q2 Earnings Snapshot

OMCL : 45.69 (+3.58%)
Omnicell: Q1 Earnings Snapshot

Omnicell: Q1 Earnings Snapshot

OMCL : 45.69 (+3.58%)
Omnicell: Q4 Earnings Snapshot

Omnicell: Q4 Earnings Snapshot

OMCL : 45.69 (+3.58%)
Omnicell: Q3 Earnings Snapshot

Omnicell: Q3 Earnings Snapshot

OMCL : 45.69 (+3.58%)
Omnicell: Q2 Earnings Snapshot

Omnicell: Q2 Earnings Snapshot

OMCL : 45.69 (+3.58%)
EmpiRx Health Names Healthcare and Technology Veteran Danny Sanchez as CEO

/PRNewswire/ -- EmpiRx Health, the industry's only value-based PBM, today announced that the company's president, Danny Sanchez, has been named Chief Executive...

OMCL : 45.69 (+3.58%)
Omnicell to Present at the BofA Securities 2023 Healthcare Conference

Omnicell, Inc. (NASDAQ:OMCL) (“Omnicell” or the “Company”), a leader in transforming the pharmacy care delivery model, announced that it will present at the BofA Securities 2023 Healthcare Conference...

OMCL : 45.69 (+3.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Omnicell Inc., develops and markets end-to-end automation solutions for the medication-use process. These automation solutions contain medication and supply dispensing systems, central pharmacy storage, retrieval and packaging solutions, a bedside automation solution, a physician order management solution,...

See More

Key Turning Points

3rd Resistance Point 49.00
2nd Resistance Point 47.46
1st Resistance Point 46.57
Last Price 45.69
1st Support Level 44.14
2nd Support Level 42.60
3rd Support Level 41.71

See More

52-Week High 55.74
Last Price 45.69
Fibonacci 61.8% 44.05
Fibonacci 50% 40.43
Fibonacci 38.2% 36.82
52-Week Low 25.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar